Shire (SHPG) Announces U.S. Launch of CUVITRU
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Shire Launches CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] in the U.S. for Primary Immunodeficiency
November 16, 2016 7:00 AM ESTLEXINGTON, Massachusetts, November 16, 2016 /PRNewswire/ --
CUVITRU, now available in the U.S., expands Shire's immunoglobulin portfolio of treatment options to meet the unique needs of children and adults living with primary immunodeficiencyÂ
Shire plc (LSE: SHP, NASDAQ: SHPG) announces the launch of CUVITRU [Immune Globulin Subcutaneous (Human), 20% ution], the first and only Subcutaneous 20% treatment option without proline available in the U.S. to treat adult and pediatric patients (two years of... More